Join Growin Stock Community!
Beta
Back to LLY.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
operation-income-chart

LLY Operation Income

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for LLY's Operation Income in Q1'26 shows a robust $9.19B, marking a significant increase from the previous quarter's $8.84B in Q4'25 and reflecting continued strong performance in the pharmaceutical sector. Over the period from Q2'23 to Q1'26, Operation Income has exhibited a clear upward trend, rising from $2.09B to $9.19B with an overall growth trajectory despite some quarterly fluctuations, such as a dip to $427M in Q3'23 and a temporary slowdown in Q3'24 at $1.59B. Year-over-year growth has been predominantly positive, averaging around 92% in recent quarters with peaks exceeding 350% in Q3'25, highlighting accelerating profitability driven by key product successes; notable inflection points include the sharp recovery post-Q3'23 and sustained double-digit gains since Q1'24, underscoring LLY's operational resilience and expansion. The bar chart for absolute values visually emphasizes this escalating scale, while the overlaid line chart for YoY percentages reveals volatility in growth rates but confirms no sustained declines, positioning LLY for potential FY'26 highs.